Meanwhile, the promoting effects of CEACAM1 overexpression on carboplatin chemoresistance in NSCLC resistant cells were also reversed by LY294002 treatment (figure 5(f-h)). This evidence concerns the gene CEACAM1 and non-small cell lung carcinoma.